Structural studies of the Jak and Abl kinases: a prerequisite for drug design

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/284388

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Protein tyrosine kinases (PTK) are a large, pivotal family of signalling molecules implicated in diseases such as cancer and immune related disorders. This fellowship aims to develop more potent kinase inhibitors of a number of PTKs using Cytopia’s drug discovery capability coupled with the X-ray crystallography expertise within Monash University. This innovative approach will permit a rational structure-based drug discovery platform to be established and will lead to the creation of a portfolio of phase I therapeutics, which will be of substantial benefit in the medical health area.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2008

Funding Scheme: Early Career Fellowships

Funding Amount: $360,965.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Protein Targeting And Signal Transduction

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Drug design | Protein structure | Therapeutics | Tyrosine kinase | cancer

Related Links